Single-center Transformational Study on Feasibility and Efficacy of Respiratory Motion Management Using Novel Position Fixation Device for Lung Cancer Patients Undergoing Stereotactic Body Radiation Therapy(2023 No.358 Project)
This single-center study evaluates a novel body position and breath-holding device for lung cancer patients receiving stereotactic body radiation therapy. We will enroll 50 patients with single peripheral non-small cell lung cancer, compare tumor movement and radiation dose distribution with and without the device, to test if the device is safe, feasible and can improve treatment accuracy.
調査の概要
詳細な説明
For patients with peripheral non-small cell lung cancer receiving stereotactic body radiation therapy, respiratory motion often causes target volume deviation and compromises dose accuracy to tumors and nearby organs at risk. Current standard immobilization methods have limited ability to stabilize deep breathing patterns. This single-center translational study uses an integrated body position and breath-holding device, enrolling 50 eligible patients who will undergo 4DCT scans both with and without the device while keeping their clinical SBRT treatment plan unchanged. We will compare tumor motion amplitude, target coverage, conformity index and organ dose parameters between the two scanning states, to verify the device's feasibility, safety and value in improving treatment precision, providing clinical evidence for wider application in lung SBRT.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Tianjin、中国、300000
- Tianjin Medical University Cancer Institute and Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Voluntarily participate and sign written informed consent
- Age ≥18 years, gender unlimited
- Clinically diagnosed with single peripheral lung cancer, assessed as suitable for SBRT
- Males or females of childbearing age willing to take contraceptive measures during the trial
- Female of childbearing age must have a negative pregnancy test within 7 days before treatment, and all patients use adequate contraception during treatment and for 4 weeks after
Exclusion Criteria:
- Intolerant or unwilling to receive the integrated respiratory suppression and positioning immobilization device for radiotherapy localization.
- Currently participating or planning to participate in other clinical trials.
- Refuse or be unable to sign the informed consent form for this trial.
- Patients with central or ultra-central lung cancer.
- Patients planned to receive SBRT for multiple pulmonary lesions.
- Patients assessed by the investigators of this trial as unsuitable for SBRT treatment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Single Arm - Novel Respiratory Immobilization
All enrolled patients receive 4DCT with and without the device |
A novel immobilization device used for respiratory motion management during lung stereotactic body radiation therapy |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Mean respiratory motion amplitude of GTV and organs at risk (OARs) measured on 4DCT before and after abdominal pressure immobilization
時間枠:through study completion, an average of 1 year
|
Respiratory motion amplitude (maximum displacement) of gross tumor volume (GTV) and organs at risk (OARs) will be contoured and extracted from pre-abdominal-pressure 4DCT and post-abdominal-pressure 4DCT. The difference in motion amplitude between the two states will be compared to evaluate the feasibility and effectiveness of the novel abdominal pressure positioning membrane for lung SBRT. |
through study completion, an average of 1 year
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Conformity index (CI) of SBRT planning target volume (PTV)
時間枠:At the time of SBRT plan design, prior to treatment delivery
|
CI of PTV calculated from SBRT dose distribution after abdominal pressure immobilization |
At the time of SBRT plan design, prior to treatment delivery
|
|
Coverage of planning target volume (PTV)
時間枠:At the time of SBRT plan design, prior to treatment delivery
|
PTV coverage calculated from SBRT dose distribution after abdominal pressure immobilization |
At the time of SBRT plan design, prior to treatment delivery
|
|
Maximum relative dose at 2 cm outside the PTV boundary (D2cm)
時間枠:At the time of SBRT plan design, prior to treatment delivery
|
Percentage of maximum dose at the region 2 cm outside PTV boundary on SBRT plan |
At the time of SBRT plan design, prior to treatment delivery
|
|
Volume of normal ipsilateral lung receiving ≥20Gy,15Gy,10Gy and 5Gy (V20,V15, V10, V5)
時間枠:At the time of SBRT plan design, prior to treatment delivery
|
Dose-volume histogram parameters of normal treated lung from abdominal-pressure SBRT plan |
At the time of SBRT plan design, prior to treatment delivery
|
|
Maximum dose (Dmax) to organs at risk including spinal cord, heart and esophagus
時間枠:At the time of SBRT plan design, prior to treatment delivery
|
Dmax of OARs derived from SBRT dose plan under abdominal pressure immobilization |
At the time of SBRT plan design, prior to treatment delivery
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- bc20261997
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
This is an exploratory feasibility study, and no public sharing of individual patient data is planned.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。